Study of FP-1039 in Subjects With Endometrial Cancers

NCT01244438 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Study FP1039-002 was not feasible. The original assumption was at least 5% of patients screened would qualify, but after screening 70 patients, none qualified.

Conditions

Interventions

Sponsor

Five Prime Therapeutics, Inc.

Collaborators